Jose Soumia, Hughbanks Marissa L, Binder Bernard Y K, Ingavle Ganesh C, Leach J Kent
Department of Biomedical Engineering, University of California, Davis, Davis, CA, USA.
Department of Biomedical Engineering, University of California, Davis, Davis, CA, USA; Department of Orthopaedic Surgery, University of California, Davis, School of Medicine, Sacramento, CA, USA.
Acta Biomater. 2014 May;10(5):1955-64. doi: 10.1016/j.actbio.2014.01.020. Epub 2014 Jan 24.
Recombinant proteins and cytokines are under broad preclinical and clinical investigation to promote angiogenesis, but their success is limited by ineffective delivery, lack of long-term stability and excessive cost. Mesenchymal stem/stromal cells (MSC) secrete bioactive trophic factors, and thus, may provide an effective alternative to address these challenges. Glycine-Histidine-Lysine (GHK) is a peptide fragment of osteonectin, a matricellular protein with reported proangiogenic potential. We examined the capacity of GHK to up-regulate secretion of proangiogenic factors from human MSC in culture and when covalently coupled to alginate hydrogels. GHK had no apparent cytotoxic effects on MSC in culture over a wide range of concentrations. We detected a dose-dependent increase in vascular endothelial growth factor (VEGF) concentration in media conditioned by GHK-treated MSC, which increased endothelial cell proliferation, migration and tubule formation. We covalently coupled GHK to alginate using carbodiimide chemistry, and human MSC were entrapped in alginate hydrogels to assess VEGF secretion. Similar to monolayer culture, MSC responded to GHK-modified gels by secreting increased concentrations of VEGF and basic fibroblast growth factor compared to unmodified gels. The pre-treatment of MSC with antibodies to α6 and β1 integrins prior to entrapment in GHK-modified gels abrogated VEGF secretion, suggesting that the proangiogenic response of MSC was integrin-mediated. These data demonstrate that the proangiogenic potential of MSC can be significantly increased by the presentation of GHK with a biodegradable carrier, therefore increasing their clinical potential when used for tissue repair.
重组蛋白和细胞因子正在广泛的临床前和临床研究中用于促进血管生成,但其成功受到递送效率低、缺乏长期稳定性和成本过高的限制。间充质干/基质细胞(MSC)分泌生物活性营养因子,因此可能为应对这些挑战提供一种有效的替代方法。甘氨酸-组氨酸-赖氨酸(GHK)是骨粘连蛋白的一个肽片段,骨粘连蛋白是一种据报道具有促血管生成潜力的基质细胞蛋白。我们研究了GHK在培养物中以及与海藻酸水凝胶共价偶联时上调人MSC促血管生成因子分泌的能力。在很宽的浓度范围内,GHK对培养中的MSC没有明显的细胞毒性作用。我们检测到经GHK处理的MSC条件培养基中血管内皮生长因子(VEGF)浓度呈剂量依赖性增加,这增加了内皮细胞的增殖、迁移和小管形成。我们使用碳二亚胺化学方法将GHK与海藻酸共价偶联,并将人MSC包埋在海藻酸水凝胶中以评估VEGF分泌。与单层培养类似,与未修饰的凝胶相比,MSC对GHK修饰的凝胶的反应是分泌更高浓度的VEGF和碱性成纤维细胞生长因子。在包埋到GHK修饰的凝胶之前,用α6和β1整合素抗体对MSC进行预处理可消除VEGF分泌,这表明MSC的促血管生成反应是由整合素介导的。这些数据表明,通过用可生物降解的载体呈现GHK,可以显著提高MSC的促血管生成潜力,从而增加其用于组织修复时的临床潜力。